{"name": "MethylGene",
 "permalink": "methylgene",
 "crunchbase_url": "http://www.crunchbase.com/company/methylgene",
 "homepage_url": "http://www.methylgene.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@methylgene.com",
 "phone_number": "514.337.3333",
 "description": "",
 "created_at": "Tue Sep 07 04:03:38 UTC 2010",
 "updated_at": "Sat Mar 26 00:09:23 UTC 2011",
 "overview": "\u003Cp\u003EMethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company\u0026#8217;s product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene\u0026#8217;s HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company\u0026#8217;s proprietary kinase inhibitor chemistry.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       43],
      "assets/images/resized/0010/0804/100804v1-max-150x150.png"],
     [[177,
       51],
      "assets/images/resized/0010/0804/100804v1-max-250x250.png"],
     [[177,
       51],
      "assets/images/resized/0010/0804/100804v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman of the Board",
    "person":
     {"first_name": "Martin",
      "last_name": "Godbout",
      "permalink": "martin-godbout",
      "image": null}},
   {"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Charles",
      "last_name": "Grubsztajn",
      "permalink": "charles-grubsztajn",
      "image": null}},
   {"is_past": true,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Donald",
      "last_name": "F. Corcoran",
      "permalink": "donald-f-corcoran",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$34.5M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/cancer-drug-developer-methylgene-raises-345m/2011-03-25?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Cancer drug developer MethylGene raises $34.5M",
    "raised_amount": 34500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 3,
    "funded_day": 25,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "7220 Frederick-Banting",
    "address2": "",
    "zip_code": "H4S 2A1",
    "city": "Montreal, Quebec",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "METHYLGENE ENTERS INTO $15 MILLION\r\nEQUITY LINE FACILITY AGREEMENT",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 16,
    "source_url": "http://www.methylgene.com/content.asp?node=396",
    "source_text": "",
    "source_description": "METHYLGENE ENTERS INTO $15 MILLION EQUITY LINE FACILITY AGREEMENT",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "MethylGene",
      "permalink": "methylgene"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}